返回 Agenda
SESSION 3: STUDY DESIGN
Session Chair(s)
Kerry Gordon
Senior Director, Biostatistics, Japan, China, Europe and North America
IQVIA, United Kingdom
James Matcham
Head, Early Clinical Development Biometrics
AstraZeneca, United Kingdom
The objective of this session is to review different types of study design, the use of interim analyses and the importance of minimising bias.
- Parallel group designs
- Cross-over designs
- Other common phase 2 designs
- Choice of the control
- Treatment allocation
- Interim analyses
- Minimising bias
Speaker(s)
STUDY DESIGN
James Matcham
AstraZeneca, United Kingdom
Head, Early Clinical Development Biometrics